Related Experiment Video
Updated: Apr 28, 2026
Development of an Insert Co-culture System of Two Cellular Types in the Absence of Cell-Cell Contact
Published on: July 17, 2016
Myeloma Precursors Erode Durable Immunity: Results of the IMPACT study
Irene Ghobrial1,2,3,4, Noe Perron1,2,3,4, Michelle Aranha1,4
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract:
Multiple myeloma (MM) is a plasma cell malignancy marked by profound immune dysfunction and substantial infection-related mortality. MM is preceded by the asymptomatic precursor states monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), yet whether these patients can mount effective immune responses remains unknown. In this prospective observational study of 731 individuals recruited nationwide through Dana-Farber Cancer Institute, we used SARS-CoV-2 vaccination as a standardized immunological challenge alongside childhood vaccine serology. We show that precursor myeloma is associated with broad dysfunction across innate and adaptive immunity, including accelerated antibody waning, erosion of childhood vaccine titers, impaired antigen-specific T cell expansion, and blunted innate activation. Mechanistically, we link these defects to tumor burden-dependent APRIL depletion and downregulation of APRIL-responsive pathways in normal plasma cells, validated in an independent cohort. These findings have direct implications for cancer vaccine development, immunotherapy, and infection management in early-stage hematologic malignancies.
Insights
Individuals with early myeloma precursor conditions show widespread immune system defects, impacting their ability to fight infections and respond to vaccines. This immune dysfunction is linked to tumor burden and affects normal plasma cells.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Multiple myeloma (MM) is a plasma cell cancer characterized by severe immune dysfunction and high infection-related mortality.
- Precursor conditions, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), precede MM, but their impact on immune response is unclear.
Purpose of the Study:
- To investigate immune function in patients with MGUS and SMM.
- To assess the impact of precursor myeloma on innate and adaptive immunity using standardized immunological challenges.
Main Methods:
- Prospective observational study of 731 individuals nationwide.
- Utilized SARS-CoV-2 vaccination as an immunological challenge.
- Assessed childhood vaccine serology, antibody waning, T cell responses, and innate immune activation.
Main Results:
- Precursor myeloma is associated with broad immune dysfunction, affecting both innate and adaptive immunity.
- Observed accelerated antibody waning, reduced childhood vaccine titers, impaired T cell expansion, and blunted innate activation.
- Mechanisms identified include tumor burden-dependent APRIL depletion and altered APRIL-responsive pathways.
Conclusions:
- Early-stage hematologic malignancies like precursor myeloma are linked to significant immune deficits.
- Findings have implications for cancer vaccine development, immunotherapy, and infection control in these patient populations.
More Related Videos
Related Concept Videos
01:23Cells of the Adaptive Immune Response
01:15Differentiation of Common Myeloid Progenitor Cells
01:40Cell-mediated Immune Responses